
Barclays raised the firm’s price target on LivaNova (LIVN) to $120 from $105 and keeps an Overweight rating on the shares. The firm says the company’s “strong” Q3 report increases
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LIVN | LivaNova | 92.44 | 38.80 | 72.33% |
| Name | Price | % Change | |
|---|---|---|---|
| $92.44 | +72.33% |

Barclays raised the firm’s price target on LivaNova (LIVN) to $120 from $105 and keeps an Overweight rating on the shares. The firm says the company’s “strong” Q3 report increases

Mizuho raised the firm’s price target on LivaNova (LIVN) to $115 from $95 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source for

Baird raised the firm’s price target on LivaNova (LIVN) to $111 from $95 and keeps an Outperform rating on the shares. The firm updated its model following beat and raise

LivaNova PLC (($LIVN)) has held its Q3 earnings call. Read on for the main highlights of the call. LivaNova delivered a strongly positive third quarter, with revenue, operating income and

Jefferies raised the firm’s price target on LivaNova (LIVN) to $120 from $100 and keeps a Buy rating on the shares following strong Q3 results and raised guidance. The firm

Needham raised the firm’s price target on LivaNova (LIVN) to $112 from $93 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

Raises FY26 revenue view up 9%-10% from 8%-9%. Consensus is for FY26 EPS $4.36 and for revenue $1.52B. Foreign currency is expected to be a tailwind of approximately 1% based

Reports Q3 revenue $393.1M, consensus $381.11M. “Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies,” said Vladimir

The F/m Emerald Life Sciences Innovation ETF (LFSC) ranks in the 12th percentile of Morningstar’s US Fund Health category, measured against 154 funds over the trailing one-year period as of

LivaNova (LIVN) announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Assigned | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Sep 2, 2026 | ||||
| hold | Reiterated | Aug 20, 2026 | ||||
| buy | Reiterated | Aug 5, 2026 | ||||
| buy | Assigned | Jun 22, 2026 | ||||
| hold | Reiterated | May 6, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 24, 2027TBA | $5.03B | $0.97 | $389.18M | 0.03 | 25.51 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.